Understanding prostate cancer differences between African American and European American men
Official title: Developing Functional Human Cell Models to Study Initiation and Progression of Prostate Cancer between AA and EA men
Funded at Ohio State University · NIH-11079446 · Data updated 2026-11-12
This study is looking at how prostate cancer affects African American and European American men differently by creating special cell models, which could help us understand why African American men have higher rates of this cancer and find better ways to prevent and treat it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | May 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $537,842 |
| NIH project number | 5R01CA276474-03 |
| Project ID | NIH-11079446 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include African American and European American men diagnosed with prostate cancer or at risk of developing it.
✕Less likely to help
Patients with prostate cancer who are not of African American or European American descent may not receive direct benefits from this research.
What this research studies
This research investigates the biological differences in prostate cancer between African American (AA) and European American (EA) men by developing functional human cell models. The study utilizes a technique called Conditional Reprogramming (CR) to create cell cultures from normal and cancerous prostate tissues, allowing researchers to explore how these cells behave and differ in their response to cancer. By examining these differences, the research aims to uncover the underlying reasons for the higher incidence and mortality rates of prostate cancer in AA men compared to EA men. This could lead to more effective prevention and treatment strategies tailored to these populations.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for prostate cancer, particularly for African American men who are disproportionately affected.
How similar studies have gone: Previous research using Conditional Reprogramming technology has shown promise in developing human cancer models, indicating potential for success in this novel approach.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Liu, Xuefeng — Ohio State University
- Study coordinator: Liu, Xuefeng
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.